Although chimeric antigen receptor (CAR) T cell therapy (CAR-T) has altered the treatment
landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority …

Since its FDA approval, chimeric antigen receptor (CAR)-T cell therapy is changing the
landscape of the treatment algorithm for relapsed and refractory large cell lymphoma and …

PURPOSE Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell
lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells …

Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable
remission in approximately 60% of patients. In relapsed or refractory disease, only about …

Autologous hematopoietic cell transplantation (auto-HCT) has long been the standard
approach for patients with relapsed/refractory (R/R) chemosensitive diffuse large B cell …

Despite the success of CD19-targeted chimeric antigen receptor (CAR T)-cell therapy in
patients with relapsed/refractory large B-cell lymphoma (LBCL), there is a need for effective …

Most patients receiving chimeric antigen receptor T-cell therapy (CAR-T) for aggressive B-
cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel …

In recent years, chimeric antigen receptor T-cell therapy (CAR T) has revolutionized the
treatment landscape for large B cell lymphoma (LBCL), demonstrating remarkable efficacy …

This study retrospectively evaluated the outcome of salvage therapy in 51 patients who
failed axicabtagene ciloleucel or tisagenlecleucel for relapsed/refractory large B‐cell …

Chimeric antigen receptor (CAR) T‐cell (CAR‐T) therapy can provide durable remission in
patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) after failure of …